Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,668 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07508358 | Vaginal Sildenafil for Primary Dysmenorrhea(SILDYS) | not yet recruiting | Phase 1 | 10 | Kevin HellmanOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | not yet recruiting | Phase 1 | 8 | Yong HeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | not yet recruiting | Phase 1 | 74 | TwoStep Therapeutics, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07803653 | IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer | not yet recruiting | Phase 1 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07796490 | Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07783282 | A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | not yet recruiting | Phase 1 | 56 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Aug 24, 2026 | clinicaltrials |
| NCT07778498 | A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 150 | Phrontline BiopharmaINDUSTRY | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07772882 | Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer | not yet recruiting | Phase 1 | 24 | Rebecca ArendOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07765940 | Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer(COPRA424) | not yet recruiting | Phase 1 / Phase 2 | 52 | RadAlliance Therapeutics, IncINDUSTRY | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07756593 | Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer | not yet recruiting | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | not yet recruiting | Phase 1 / Phase 2 | 67 | CoRegen, Inc.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07716735 | Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer | not yet recruiting | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07743541 | Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy(NAPISTAR 1-03) | not yet recruiting | Phase 1 / Phase 2 | 100 | Tubulis GmbHINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07715747 | A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 128 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer(RegeNovar) | not yet recruiting | Phase 1 / Phase 2 | 43 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07682649 | Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer(ESCENDO) | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683013 | Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 18 | Hyundai Bioscience Co., Ltd.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07679841 | Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients(COLOMBE) | not yet recruiting | Phase 1 / Phase 2 | 50 | Centre Leon BerardOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | not yet recruiting | Phase 1 | 19 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07664735 | A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | not yet recruiting | Phase 1 | 30 | Outpace Bio, Inc.INDUSTRY | 0 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07636707 | QLF4113 in Participants With Metastatic Prostate Cancer | not yet recruiting | Phase 1 | 140 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07495293 | Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer | not yet recruiting | Phase 1 | 20 | Yonsei UniversityOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT07564102 | dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy | not yet recruiting | Phase 1 / Phase 2 | 30 | Mochida Medical USA, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | not yet recruiting | Phase 1 | 48 | Kumquat Biosciences Inc.INDUSTRY | 0 | Apr 21, 2026 | clinicaltrials |
| NCT07532148 | Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | not yet recruiting | Phase 1 | 24 | Chong Kun Dang PharmaceuticalINDUSTRY | 0 | Apr 15, 2026 | clinicaltrials |
| NCT07462468 | A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer. | not yet recruiting | Phase 1 | 36 | WestVac Biopharma Co., Ltd.INDUSTRY | 0 | Mar 13, 2026 | clinicaltrials |
| NCT07468396 | A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer | not yet recruiting | Phase 1 | 65 | Gan & Lee Pharmaceuticals.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. | not yet recruiting | Phase 1 / Phase 2 | 24 | University of ChicagoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07273396 | Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 53 | Seoul National University HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT07244393 | Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 30 | Cellbion Co., Ltd.INDUSTRY | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07172126 | Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets | not yet recruiting | Phase 1 / Phase 2 | 291 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07104110 | Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 50 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Aug 5, 2025 | clinicaltrials |
| NCT07104617 | Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | not yet recruiting | Phase 1 / Phase 2 | 48 | TYK Medicines, IncINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07088588 | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 105 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT06602063 | Surgery for Relapsed Ovarian Cancer in Precision | not yet recruiting | Phase 1 / Phase 2 | 33 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06990516 | SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 90 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy(PRODIGY-1) | not yet recruiting | Phase 1 / Phase 2 | 500 | CHU de Quebec-Universite LavalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
Data updated 13 hours agoSource updated Sep 29, 2026source: clinicaltrials